Gladius Capital Management LP Century Therapeutics, Inc. Transaction History

Gladius Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Dec 18, 2023	BUY	$2.0 - $3.23 $7,128 - $11,511	3,564 Added 57.06%	9,810 $19,000
Q3 2023 Oct 10, 2023	BUY	$2.0 - $3.23 $7,128 - $11,511	3,564 Added 57.06%	9,810 $20,000
Q2 2023 Dec 18, 2023	SELL	$2.91 - $3.53 $10,371 - $12,580	-3,564 Reduced 36.33%	6,246 $19,000
Q2 2023 Aug 08, 2023	SELL	$2.91 - $3.53 $4,318 - $5,238	-1,484 Reduced 19.2%	6,246 $20,000
Q1 2023 Dec 18, 2023	SELL	$3.4 - $5.11 $7,072 - $10,628	-2,080 Reduced 21.2%	7,730 $26,000
Q1 2023 May 09, 2023	BUY	$3.4 - $5.11 $26,282 - $39,500	7,730 New	7,730 $27,000

36.9M

8.7K

10.2K

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $61.8M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.